Lilly CEO Prescribes Greater Transparency, Coverage For Healthcare System
Executive Summary
One way to control rising healthcare costs would be through greater pricing transparency, including for pharmaceuticals, Lilly CEO Sidney Taurel suggested
You may also be interested in...
Rx Prices Reflect “Anticipated Income,” Not R&D Costs, Pfizer CEO Says
Pharmaceutical pricing decisions are based on "anticipated income" rather than achieving a return on R&D costs, Pfizer CEO Hank McKinnell writes in his recently published book A Call To Action: Taking Back Healthcare for Future Generations
PhRMA Marketing Code Prohibits Personal Gifts To Physician
The Pharmaceutical Research & Manufacturers of America marketing code includes an explicit prohibition on "items intended for the personal benefit of healthcare professionals.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011